Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trialKeunchil Park, Luis Paz‐Ares, Scott A. Laurie et al.|The Lancet Oncology|2016Cited by 1.2k
Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR MutationNan Chen, Li Zhang|Journal of Thoracic Oncology|2015Cited by 682
A B7H3-targeting antibody–drug conjugate in advanced solid tumors: a phase 1/1b trialYuxiang Ma, Hongyun Zhao, Yunpeng Yang et al.|Nature Medicine|2025Cited by 76
Expert consensus on treatment for stage III non‐small cell lung cancerYi‐Long Wu, Yun Fan, Shun Lü et al.|Medicine Advances|2023Cited by 18
Impact of gefitinib in early stage treatment on circulating cytokines and lymphocytes for patients with advanced non–small cell lung cancerSheng Jin, Li Zhang|OncoTargets and Therapy|2017Cited by 17